CONTEXT AND OBJECTIVE: Overviews of Systematic Reviews (OoRs) are a new type of study in which multiple evidence from systematic reviews (SRs) is compiled into an accessible and useful document. The aim here was to describe the state of the art and critically assess Cochrane OoRs that have been published. DESIGN AND SETTING: Descriptive study conducted at a research center.
INTRODUCTION
Overviews of Systematic Reviews (OoRs) are a new type of study that has been proposed by the Cochrane Collaboration in order to compile multiple evidence from systematic reviews (SRs) into a single document that is accessible and useful. Each OoR focuses on a problem or medical condition for which two or more SRs have addressed potential interventions and their outcomes. [1] [2] [3] [4] [5] [6] One SR rarely addresses all potential interventions for a condition, and healthcare policymakers may have difficulty in finding, evaluating, comparing and summarizing the information from all the relevant SRs. 3, 4 Thus, the main objective of OoRs is to serve as a friendly front end for the Cochrane Collaboration with regard to healthcare decision-making. The relevant SRs are integrated and/or summarized into a single document, i.e. an OoR.
This, in theory, allows the reader to have access to an integrated summary of a long list of studies included in Cochrane SRs. [1] [2] [3] [4] [5] [6] Therefore, the primary audience for OoRs are healthcare decision-makers, such as healthcare professionals, policymakers and informed consumers who, through the Cochrane Library, seek evidence on treatments for various health conditions.
1,2
The first part 1,2 of this series of three articles on OoRs focused on the growth of publications with the best level of evidence available for healthcare decision-making. It provided justifications for implementing this new type of study, as well as defining who the target audience are. Furthermore, a filter was created and applied in order to search for specific OoRs in the Cochrane Library.
This second part of the series continues to address this topic by describing the state of the art (state of knowledge)
of Cochrane Collaboration OoRs, through a critical assessment of Cochrane OoRs. In Part III, a new hierarchy for the pyramid of evidence will be proposed, taking this new type of study into consideration.
OBJECTIVE
To critically assess Cochrane Overviews of Systematic Reviews, through analyzing the characteristics, approaches and methodological aspects of this type of study.
METHODS
This descriptive study was conducted at the research center of a federal university in Brazil and within one of its postgraduate study programs.
We performed a search for OoRs in the Cochrane Library, as described in Part I 1,2 of this series. The flowchart for the OoRs is shown in Figure 1 . The inclusion criteria were that the studies needed to be OoRs and to have been published in the Cochrane Database of Systematic Reviews, which is one of the six directories of the Cochrane Library. 7 Protocols for Cochrane OoRs that have been published were excluded.
After OoR selection, two of the present authors (VS and AJG) read them, extracted data and assessed the quality. Differences in data collection information were resolved by reaching a consensus.
The data extracted from each OoR were organized using a specific form that sought information on the research question and objective, date of search, number of studies included, participants, interventions, main outcome, methodological quality of the review, quality of evidence and authors' conclusion.
We used five items to critically assess the OoRs: (1) Data synthesis was performed using descriptive statistics.
Contingency tables were used to summarize dichotomous data as frequencies and proportions. Quantitative data were summarized using the mean and standard deviation. Sensitivity analysis were performed to assess the robustness of the results.
RESULTS
The search filter for OoRs that was developed in Part I 1,2 of this study was updated, validated 9 [sensitivity = 1.00 (95% CI = 0.86 to 1.00); specificity = 0.99 (95% CI = 0.99 to 1.00)] and used (on November 5, 2013) . Through this process, 1207 titles were retrieved, of which 95% were excluded because they had not been published in the Cochrane Database of Systematic Reviews.
Ninety-three references were checked, but 52 of these were systematic reviews and were excluded; and another 26 potential OoRs were excluded because they were at the protocol stage.
At the end of the selection process, 13 OoRs 26,35-46 were included, were used for data extraction and were critically assessed. The characteristics of the thirteen OoRs 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] included in this study are described in detail in Appendix 1, which includes the main conclusions from the approaches used in each study.
The synthesis on the data extracted from these 13 OoRs, 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] with the overall assessment, is presented in With regard to judging the quality of evidence, it was found that many categories/studies were unclear, and thus the proportion of the categories/studies that presented high-quality evidence was low. If the OoRs 40, 42, 46 in which more than 10% of the studies/categories could not be clearly judged regarding the quality of evidence were excluded, the proportion of studies/categories that were of high quality doubled. The sensitivity analysis drastically altered the proportions of the other categories regarding the quality of evidence ( Table 1) .
Through the outcome of implications for practice, we found that about 64% of the interventions were judged to be beneficial or harmful. However, there was insufficient evidence to judge the interventions in 36% of them ( Table 1) .
Regarding general factors, with a 95% confidence interval, we expect that each new OoR will include between 9,462 and 64,469
patients, between 9 and 29 SRs and between 80 and 344 primary studies, and will assess between 6 and 21 interventions. Between 50
and 92% of OoRs that pool data qualitatively will generate between 2 and 26 meta-analyses. Additional details are analyzed in Table 1 .
Studies identified in the Cochrane Library (n = 1,207) Studies not published in Cochrane Database of Systematic Reviews (n = 1,114) Studies identified in the Cochrane Database of Systematic Reviews (n = 93) Studies excluded because they were not OoRs (n = 52)
OoRs excluded because they were protocols (n = 25) OoRs assessed for inclusion (n = 41)
OoRs included for analysis (n = 13) 39, [41] [42] [43] 46 in which additional searches in the CDSR were conducted were included in the analysis; i the protocols for these OoRs 37, 39 were not found in the Cochrane Library or in Archie, thus reducing the number of OoRs in the analysis; SD = standard deviation; range = minimum to maximum; SR = systematic review.
Most of the OoRs (62%) conducted searches for systematic reviews only in the Cochrane Database of Systematic Reviews (CDSR). However, those that conducted external searches, in addition to searching in the CDSR, used between one and ten databases ( Table 1) . Table 1 also shows that, from the date when the OoR title was registered, the authors spent about two years (about one year for planning/preparing the protocol and another year for implementing the full study) until the date of publication.
Only 23% (3/13) of the OoRs did not identify the study type in the title. The same also occurred in the protocols for OoRs (6/28). Despite the high methodological quality of the study by Ryan et al., 40 it only described how the systematic reviews included had assessed the quality of evidence, thus making it difficult to assess this outcome. Many studies (890/2141) may not have made judgments regarding the quality of evidence. In the second of these OoRs, Jones et al. 42 used the Cochrane risk of bias tool 58, 61 to assess the quality of the evidence in Cochrane reviews, while for non-Cochrane reviews they used Jadad et al. 60 Despite the differences in the concepts of quality of evidence and methodological quality (which were not among the objectives of this discussion), these authors reported the proportion of studies that presented high quality. Thus, the description was not sufficiently clear or standardized for a judgment to be made regarding the overall quality of evidence.
DISCUSSION
To assess the quality of evidence, the most consistently used method among the OoRs assessed 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] was the GRADE approach. 57 Basically, this tool classifies evidence into four levels:
(1) high quality -it is unlikely that future research will change the estimated effect; (2) OoRs. To reduce the inconsistency of OoRs, it is important that authors follow the existing methodological recommendations. 3, 5, 61 When extracting data, attention was drawn to two factors:
(1) three studies 37, 39, 43 did not declare the type of study, i.e. "overview of reviews" (there was a similar proportion with regard to protocols for OoRs: 6/28), which may be a limiting factor in that it becomes more difficult for readers to easily identify the type of study; (2) Singh et al. 41 only included primary studies from the list of references of systematic reviews and conducted search strategies in bibliographic databases.
Another feature that may pose a challenge in conducting this type of study is the complex statistical methods required for integrate and summarizing the evidence. The methodological basis for network meta-analysis, also known as multipletreatment meta-analysis and mixed-treatment comparisons, was established in 1996. 52 In view of the challenge of imple- In Part III, a new hierarchy for the pyramid of evidence will be proposed, taking this new type of study into consideration.
CONCLUSION
OoRs have high methodological quality and high quality of evidence, as assessed in general. Moreover, about two-thirds of the conclusions had sufficient evidence to judge that the implications for practice were either beneficial or harmful. In order to do this, the mean length of work required was 24 months. The profile of OoRs reduces uncertainty in decision-making.
This new type of study demonstrates the ability to compile multiple evidence from systematic reviews in one handy and useful document that is able to address all potential interventions for a condition, thereby allowing decision-makers to locate, evaluate, compare and summarize the evidence from systematic reviews or primary studies.
Although OoRs are able to integrate and summarize multiple interventions for a problem in a single document, there is still a need to standardize the methods for this new type of study.
Appendix 1.
Characteristics of Cochrane Overviews of Systematic Reviews (OoRs) that were included. Interventions:
Biological disease-modifying anti-rheumatic drugs (DMARDs) (including abatacept, adalimumab, anakinra, etanercept, infliximab, rituximab and other biological DMARDs) used alone in standard approved doses or in combination with other biological/traditional DMARDs, compared with placebo alone or with placebo plus biological/traditional DMARD.
Main outcomes:
ACR50, defined as 50% improvement in both tender and swollen joint counts and 50% improvement in three of the following five variables: patient overall assessment, physician overall assessments, pain scores, Health Assessment Questionnaire (HAQ) score and acute-phase reactants: erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). ACR50 was chosen because clinical and statistical evidence shows that this is the preferred endpoint for contemporary rheumatoid arthritis clinical trials; withdrawal due to adverse events was used as a proxy measurement of safety. Quality of the OoR:
High quality (10 points in AMSTAR). Quality of the evidence:
The results were graded as 'moderate' using the GRADE approach.
Authors' conclusion:
In the absence of direct comparisons of biological DMARDs in patients with rheumatoid arthritis, practitioners are faced with a dilemma when choosing biological DMARDs. Anakinra was less efficacious than the other five biologics and etanercept led to lower withdrawal rates due to adverse events, compared with adalimumab, anakinra and infliximab. Future randomized controlled trials should use direct head-to-head comparisons of biological agents in patients with rheumatoid arthritis. Keus et al. 36 Review Mortality; complications (including subcategories); symptom relief. Quality of the OoR:
High quality (8 points in AMSTAR).
Quality of the evidence:
The overall quality of the randomized trials included varied given that most of the trials had several methodological deficiencies.
Authors' conclusion:
No statistically significant differences in the outcome measurements of mortality and complications were found between open, small-incision and laparoscopic cholecystectomy. There were no data on symptom relief. Complications from elective cholecystectomy are high. The quicker recovery of both laparoscopic and small-incision cholecystectomy patients, compared with patients undergoing open cholecystectomy, justifies using these two approaches. Research should concentrate on outcomes that are relevant to patients instead of focusing on outcomes that are of interest mainly to surgeons. Amato et al. 37 Review question/objective: What are the efficacy and safety of pharmacological interventions for treating Alcohol Withdrawal Syndrome? Search methods:
December 30, 2010. Studies included:
Five systematic reviews. Participants:
Alcohol-dependent patients diagnosed in accordance with appropriate standardized criteria.
Interventions: Pharmacological interventions alone or in combination with other drugs or placebo; and other pharmacological interventions.
Alcohol withdrawal seizures; alcohol withdrawal delirium; alcohol withdrawal symptoms as measured using prespecified scales (such as the CIWA-Ar score); craving as measured using validated scales; adverse events; and severe, life-threatening adverse events. Quality of the OoR:
The majority of study results were graded as very low or low quality using the GRADE approach.
Between the four treatments considered, benzodiazepines showed a protective benefit against alcohol withdrawal symptoms, in particular seizures. Further studies should test alternative drugs, and should investigate which benzodiazepine performed best for treating alcohol withdrawal syndrome and the relative dose-response effect.
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